These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 24439375)

  • 1. Potentiated Hsp104 variants antagonize diverse proteotoxic misfolding events.
    Jackrel ME; DeSantis ME; Martinez BA; Castellano LM; Stewart RM; Caldwell KA; Caldwell GA; Shorter J
    Cell; 2014 Jan; 156(1-2):170-82. PubMed ID: 24439375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic genetic variation revealed in diverse Hsp104 homologs.
    March ZM; Sweeney K; Kim H; Yan X; Castellano LM; Jackrel ME; Lin J; Chuang E; Gomes E; Willicott CW; Michalska K; Jedrzejczak RP; Joachimiak A; Caldwell KA; Caldwell GA; Shalem O; Shorter J
    Elife; 2020 Dec; 9():. PubMed ID: 33319748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potentiated Hsp104 variants suppress toxicity of diverse neurodegenerative disease-linked proteins.
    Jackrel ME; Shorter J
    Dis Model Mech; 2014 Oct; 7(10):1175-84. PubMed ID: 25062688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isolating potentiated Hsp104 variants using yeast proteinopathy models.
    Jackrel ME; Tariq A; Yee K; Weitzman R; Shorter J
    J Vis Exp; 2014 Nov; (93):e52089. PubMed ID: 25407485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mining Disaggregase Sequence Space to Safely Counter TDP-43, FUS, and α-Synuclein Proteotoxicity.
    Tariq A; Lin J; Jackrel ME; Hesketh CD; Carman PJ; Mack KL; Weitzman R; Gambogi C; Hernandez Murillo OA; Sweeny EA; Gurpinar E; Yokom AL; Gates SN; Yee K; Sudesh S; Stillman J; Rizo AN; Southworth DR; Shorter J
    Cell Rep; 2019 Aug; 28(8):2080-2095.e6. PubMed ID: 31433984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanistic Insights into Hsp104 Potentiation.
    Torrente MP; Chuang E; Noll MM; Jackrel ME; Go MS; Shorter J
    J Biol Chem; 2016 Mar; 291(10):5101-15. PubMed ID: 26747608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversing deleterious protein aggregation with re-engineered protein disaggregases.
    Jackrel ME; Shorter J
    Cell Cycle; 2014; 13(9):1379-83. PubMed ID: 24694655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engineering therapeutic protein disaggregases.
    Shorter J
    Mol Biol Cell; 2016 May; 27(10):1556-60. PubMed ID: 27255695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tuning Hsp104 specificity to selectively detoxify α-synuclein.
    Mack KL; Kim H; Barbieri EM; Lin J; Braganza S; Jackrel ME; DeNizio JE; Yan X; Chuang E; Tariq A; Cupo RR; Castellano LM; Caldwell KA; Caldwell GA; Shorter J
    Mol Cell; 2023 Sep; 83(18):3314-3332.e9. PubMed ID: 37625404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineering enhanced protein disaggregases for neurodegenerative disease.
    Jackrel ME; Shorter J
    Prion; 2015; 9(2):90-109. PubMed ID: 25738979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drivers of Hsp104 potentiation revealed by scanning mutagenesis of the middle domain.
    Ryan JJ; Bao A; Bell B; Ling C; Jackrel ME
    Protein Sci; 2021 Aug; 30(8):1667-1685. PubMed ID: 34010483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Applying Hsp104 to protein-misfolding disorders.
    Vashist S; Cushman M; Shorter J
    Biochem Cell Biol; 2010 Feb; 88(1):1-13. PubMed ID: 20130674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potentiating Hsp104 activity via phosphomimetic mutations in the middle domain.
    Tariq A; Lin J; Noll MM; Torrente MP; Mack KL; Murillo OH; Jackrel ME; Shorter J
    FEMS Yeast Res; 2018 Aug; 18(5):. PubMed ID: 29788207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Applying chaperones to protein-misfolding disorders: molecular chaperones against α-synuclein in Parkinson's disease.
    Chaari A; Hoarau-Véchot J; Ladjimi M
    Int J Biol Macromol; 2013 Sep; 60():196-205. PubMed ID: 23748003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Operational plasticity enables hsp104 to disaggregate diverse amyloid and nonamyloid clients.
    DeSantis ME; Leung EH; Sweeny EA; Jackrel ME; Cushman-Nick M; Neuhaus-Follini A; Vashist S; Sochor MA; Knight MN; Shorter J
    Cell; 2012 Nov; 151(4):778-793. PubMed ID: 23141537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conserved distal loop residues in the Hsp104 and ClpB middle domain contact nucleotide-binding domain 2 and enable Hsp70-dependent protein disaggregation.
    Desantis ME; Sweeny EA; Snead D; Leung EH; Go MS; Gupta K; Wendler P; Shorter J
    J Biol Chem; 2014 Jan; 289(2):848-67. PubMed ID: 24280225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disparate Mutations Confer Therapeutic Gain of Hsp104 Function.
    Jackrel ME; Yee K; Tariq A; Chen AI; Shorter J
    ACS Chem Biol; 2015 Dec; 10(12):2672-9. PubMed ID: 26441009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suramin inhibits Hsp104 ATPase and disaggregase activity.
    Torrente MP; Castellano LM; Shorter J
    PLoS One; 2014; 9(10):e110115. PubMed ID: 25299406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural and mechanistic insights into Hsp104 function revealed by synchrotron X-ray footprinting.
    Sweeny EA; Tariq A; Gurpinar E; Go MS; Sochor MA; Kan ZY; Mayne L; Englander SW; Shorter J
    J Biol Chem; 2020 Feb; 295(6):1517-1538. PubMed ID: 31882541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective Hsp70-Dependent Docking of Hsp104 to Protein Aggregates Protects the Cell from the Toxicity of the Disaggregase.
    Chamera T; Kłosowska A; Janta A; Wyszkowski H; Obuchowski I; Gumowski K; Liberek K
    J Mol Biol; 2019 May; 431(11):2180-2196. PubMed ID: 31026451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.